View Item 

Show simple item record

Safety of Daptomycin in Patients Receiving Hemodialysis
dc.contributor.authorMueller, Bruce A.en_US
dc.contributor.authorCrompton, Jason A.en_US
dc.contributor.authorDonovan, Brian J.en_US
dc.contributor.authorYankalev, Saraen_US
dc.contributor.authorLamp, Kenneth C.en_US
dc.date.accessioned2012-03-16T16:01:21Z
dc.date.available2012-09-04T15:28:01Zen_US
dc.date.issued2011-07en_US
dc.identifier.citationMueller, Bruce A.; Crompton, Jason A.; Donovan, Brian J.; Yankalev, Sara; Lamp, Kenneth C. (2011). "Safety of Daptomycin in Patients Receiving Hemodialysis." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31(7). <http://hdl.handle.net/2027.42/90386>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90386
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherAntibioticsen_US
dc.subject.otherDaptomycinen_US
dc.subject.otherGram‐Positive Infectionen_US
dc.subject.otherHemodialysisen_US
dc.subject.otherStaphylococcus Aureusen_US
dc.subject.otherVancomycinen_US
dc.titleSafety of Daptomycin in Patients Receiving Hemodialysisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherClinical Development and Medical Affairs, Cubist Pharmaceuticals, Inc., Lexington, Massachusettsen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90386/1/phco.31.7.665.pdf
dc.identifier.doi10.1592/phco.31.7.665en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceSalama NH, Segal JH, Churchwell MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 2009; 4: 1190 – 4.en_US
dc.identifier.citedreferenceFoley RN. Infections in patients with chronic kidney disease. Infect Dis Clin North Am 2007; 21: 659 – 72.en_US
dc.identifier.citedreferenceBerman SJ, Johnson EW, Nakatsu C., Alkan M., Chen R., LeDuc J. Burden of infection in patients with end‐stage renal disease requiring long‐term dialysis. Clin Infect Dis 2004; 39: 1747 – 53.en_US
dc.identifier.citedreferenceU.S. Centers for Disease Control and Prevention. Invasive methicillin‐resistant Staphylococcus aureus infections among dialysis patients: United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56: 197 – 9.en_US
dc.identifier.citedreferenceRybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 ( suppl 1 ): S35 – 9.en_US
dc.identifier.citedreferenceHidayat LK, Hsu DI, Quist R., Shriner KA, Wong‐Beringer A. High‐dose vancomycin therapy for methicillin‐resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138 – 44.en_US
dc.identifier.citedreferenceMacLayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case‐control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006; 28: 1208 – 16.en_US
dc.identifier.citedreferenceSakoulas G., Moise‐Broder PA, Schentag J., Forrest A., Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin‐resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398 – 402.en_US
dc.identifier.citedreferenceU.S. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565 – 7.en_US
dc.identifier.citedreferenceDawn M., Sievert DM, Rudrik JT, et al. Vancomycin‐resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis 2008; 46: 668 – 74.en_US
dc.identifier.citedreferenceMalani PN, Rana MM, Banerjee M., Bradley SF. Staphylococcus aureus bloodstream infections: the association between age and mortality and functional status. J Am Geriatr Soc 2008; 56: 1485 – 9.en_US
dc.identifier.citedreferenceBlot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin‐susceptible and methicillin‐resistant Staphylococcus aureus. Arch Intern Med 2002; 162: 2229 – 35.en_US
dc.identifier.citedreferenceKang CI, Song JH, Ko KS, Chung DR, Peck KR, for the Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical features and outcome of Staphylococcus aureus infection in elderly versus younger adult patients. Int J Infect Dis 2011; 15: e58 – 62.en_US
dc.identifier.citedreferenceMascio CTM, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary‐phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007; 51: 4255 – 60.en_US
dc.identifier.citedreferenceSader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus. isolates from hemodialysis patients Int J Infect Dis 2009; 13: 291 – 5.en_US
dc.identifier.citedreferenceArbeit RD, Maki D., Tally FP, Campanaro E., Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin‐structure infections. Clin Infect Dis 2004; 38: 1673 – 81.en_US
dc.identifier.citedreferenceFowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653 – 65.en_US
dc.identifier.citedreferenceDvorchik B., Arbeit RD, Chung J., Liu S., Knebel W., Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799 – 807.en_US
dc.identifier.citedreferenceCubist Pharmaceuticals. Cubicin (daptomycin for injection) full prescribing information. Available from http:www.cubicin. compdfPrescribingInformation.pdf. Accessed December 17, 2010.en_US
dc.identifier.citedreferenceRolston KVI, Segreti J., Lamp KC, Friedrich LV. Cubicin outcomes registry and experience (CORE) methodology. Am J Med 2007; 120 ( 10A ): S4 – 5.en_US
dc.identifier.citedreferenceU.S. Food and Drug Administration. Guideline for industry, clinical safety data management: definitions and standards for expedited reporting. Available from http:www.fda.govdownloadsDrugsGuidanceComplianceRegulatoryInformationGuidancesUCM073087.pdf. Accessed December 17, 2010.en_US
dc.identifier.citedreferenceWeis F., Beiras‐Fernandez A., Schelling G. Daptomycin, a lipopeptide antibiotic in clinical practice. Curr Opin Investig Drugs 2008; 9: 879 – 84.en_US
dc.identifier.citedreferenceBhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: 1568 – 74.en_US
dc.identifier.citedreferenceCubist Pharmaceuticals, Inc. Prospective multicenter randomized evaluator‐blinded comparator‐controlled study to describe the safety and efficacy of daptomycin for the treatment of CSSSI and Staphylococcus aureus bacteremia among subjects with renal impairment. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http:clinical trials.govshowNCT01104662. Accessed August 10, 2010.en_US
dc.identifier.citedreferenceAllon M., Radeva M., Bailey J., et al. The spectrum of infection‐related morbidity in hospitalized haemodialysis patients. Nephrol Dial Transplant 2005; 20: 1180 – 6.en_US
dc.identifier.citedreferenceDecker BS, Mueller BA, Sowinski KM. Drug dosing considerations in alternative hemodialysis. Adv Chronic Kidney Dis 2007; 14: e17 – 26.en_US
dc.identifier.citedreferenceHimmelfarb J. Hemodialysis complications. Am J Kidney Dis 2005; 45: 1122 – 31.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.31.7.665.pdf
Size:
131.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.